What is Acelot?
Acelot operates at the intersection of high-performance computing and molecular biology. The company is dedicated to the development of small molecule therapies designed to address the underlying mechanisms of neurodegenerative conditions. Its flagship program, ACE-2223, represents a sophisticated effort to restore the functional integrity of the TDP-43 protein, a critical biomarker and therapeutic target in ALS. By integrating AI-driven drug discovery platforms, Acelot optimizes the identification of novel candidates, effectively reducing the time-to-market for first-in-class treatments. This strategic focus on high-unmet-need patient populations positions the company as a high-value asset within the broader pharmaceutical ecosystem, attracting interest from stakeholders focused on long-term medical innovation.
How much funding has Acelot raised?
Acelot has raised a total of $8.7M across 1 funding round:
Stock/Share Issuance
$8.7M
Stock/Share Issuance (2025): $8.7M, investors not publicly disclosed
Key Investors in Acelot
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Acelot?
With this major strategic investment, Acelot is poised to accelerate its clinical development pipeline and expand its computational infrastructure. The capital will likely be deployed to advance ACE-2223 through critical regulatory milestones and to scale the company's AI-driven discovery engine. As the firm transitions into a more mature phase of enterprise-level operations, the focus will shift toward establishing strategic partnerships with global pharmaceutical entities. These collaborations will be essential for navigating the complexities of late-stage clinical trials and eventual commercialization. The company's trajectory suggests a robust commitment to transforming the standard of care for ALS patients, while simultaneously building a sustainable, technology-enabled drug discovery platform that could be applied to a wider array of protein-misfolding diseases in the future.
See full Acelot company page
